Terence M. Williams, M.D., Ph.D.
Terence M. Williams, M.D., Ph.D., joins City of Hope as a professor and chair of the Department of Radiation Oncology.
Dr. Williams specializes in treating patients with thoracic and gastrointestinal cancers, with an emphasis on nonsmall cell lung, pancreatic and hepatobiliary malignancies. Before joining City of Hope, he held several leadership roles at The James Cancer Hospital and Comprehensive Cancer Center at The Ohio State University.
Dr. Williams received his M.D. and Ph.D. from Albert Einstein College of Medicine in New York and completed his residency in radiation oncology and internship in internal medicine at University of Michigan Medical Center. Before joining City of Hope, he held several leadership roles at The James Cancer Hospital and Comprehensive Cancer Center at The Ohio State University.
He has a National Institutes of Health-funded research laboratory and has received numerous funding and awards from the National Cancer Institute, National Institutes of Health, American Society of Radiation Oncology, American Society of Clinical Oncology, American Cancer Society and the Radiologic Society of North America. He also serves as a permanent member of the National Institutes of Health Radiation Therapeutics and Biology study section, vice-chair of American Society for Radiation Oncology biology scientific programs, and serves on numerous committees for NRG Oncology and Alliance for Clinical Trials in Oncology.
His research interests are in stereotactic body radiation therapy, experimental therapeutics, radiogenomics, DNA repair, radiobiology, nutrient scavenging and theranostics.
Duarte Cancer Center
Duarte, CA 91010
Licensed Physician, State of California
Licensed Physician, State of Ohio (valid until October 1, 2021)
Licensed Physician, State of Michigan (expired January 2013)
Drug Enforcement Agency (expired May 31, 2021)
Certification, American Board of Radiology, Radiation Oncology, May 2012 (initial)
1999-2006, Ph.D. Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY
1999-2006, M.D. Medicine, Medical Scientist Training Program, Albert Einstein College of Medicine, Bronx, NY
1993-1997, B.A. Molecular and Cell Biology, Haverford College, Haverford, PA
2009-2010, Postdoctoral Research Fellow, Univ of Michigan Health System, Alnawaz Rehemtulla (Advisor)
2005-2006, Postdoctoral Research Fellow, Albert Einstein College of Medicine, Michael Lisanti (Advisor)
2009-2010, Chief Resident, Radiation Oncology, University of Michigan Health System
2007-2011, Radiation Oncology Resident, University of Michigan Health System
2006-2007, Internal Medicine Internship, University of Michigan Health System
2021-present, Professor and Chair, Department of Radiation Oncology, City of Hope, Duarte, CA
2017-2020, Physician Lead, Radiation Oncology Clinic A (GI, thoracic, sarcoma, hematologic malignancies)
2017-2020, Division Director, Thoracic and HPB Radiation Oncology, The Ohio State University
2017-2020, Associate Residency Program Director, Department of Radiation Oncology, The Ohio State University
2017-2020, Vice Chair, Translational Research, Department of Radiation Oncology, The Ohio State University
2016-2020, Associate Professor with Tenure, Department of Radiation Oncology, The Ohio State University
2011-2016, Assistant Professor, Department of Radiation Oncology, The Ohio State University
1997-1999, Research Assistant, Pediatric Oncology, Children’s Hospital of Philadelphia
2018, The Ohio State University Clinical Educator of the Year Award, Radiation Oncology
2018, Radiation Research Society, Merit travel award
2017, Co-Lead Organizer, The Ohio State University Molecular Biology Cancer Genetics Program Retreat
2016, FAME Career Development Award for Researchers, The Ohio State University Medical Center
2016, Burroughs-Wellcome Fund Travel Award (ACTS meeting)
2015, American Cancer Society Research Scholar Grant (declined due to acceptance of NIH-R01)
2015, The Ohio State University College of Medicine Faculty Achievement Award
2014, Co-Lead Organizer, The Ohio State University Molecular Biology Cancer Genetics Program Retreat
2014, K12 Training Award, First Scholar, OSU-CCC (award declined due to acceptance of KL2)
2014, KL2 Training Award, OSU Center for Clinical and Translational Sciences
2013, ASTRO Junior Faculty Career Research Training Award
2013, ASCO/AACR Methods in Clinical Cancer Research Workshop Trainee
2011, American Society of Clinical Oncology Young Investigator Award
2011, RSNA Roentgen Resident/Fellow Research Award
2011, AACR Molecular Biology in Clinical Oncology Workshop Trainee
2010, Cancer Education Consortium Molecular & Translational Oncology Workshop Fellow
2010 Radiological Society of North America Research Resident Grant
2010, American Society of Clinical Oncology Merit Award
2009, Chief Resident, Department of Radiation Oncology, University of Michigan
2009, Radiological Society of North America Research Resident Grant
2009, ASTRO Translational Symposium Travel Grant Award
2008, American Board of Radiology B. Leonard Holman Research Pathway
2005, American Society of Radiation Oncology Translational Symposium Travel Award
2003, American Association of Cancer Research Avon Foundation Scholar-in-Training Award
2019-present, International Association for the Study of Lung Cancer
2012-present, Radiation Research Society
2010-present, American Association of Cancer Research
2008-present, American College of Radiology
2008-present, American Society of Clinical Oncology
2008-present, Radiological Society of North America
2007-present, American Society for Radiation Oncology
- Tapping the potential of biology-guided radiation technology - The first City of Hope patient has been treated using RefleXion, a unique radiation platform that finds and treats tumors throughout the body in real time.
- Yang L, Shen S, Estrada-Bernal A, Robb R, Chatterjee M, Sebastian N, Webb A, Mo X, Chen W, Krishnan S, Williams TM. Oncogenic KRAS drives radioresistance through upregulation of Nrf2-53BP1-mediated non-homologous end-joining repair. Nucleic Acids Research. 2021 Nov 8;49(19):11067-11082. PMID: 34606602; PMCID: PMC8565339.
- Wolfe AR, Chablani P, Siedow MR, Miller ED, Walston S, Kendra KL, Wuthrick E, Williams TM. BRAF Mutation Correlates with Worse Local-regional Control Following Radiation Therapy in Patients with Stage III Melanoma. Radiation Oncology. 2021 Sep 18;16(1):181. PMID: 34537078; PMCID: PMC8449455.
- Robb R, Kuo JC, Liu Y, Corrales-Guerrero S, Cui T, Hegazi A, Nagy G, Lee RJ, Williams TM. A novel protein-drug conjugate, SSH20, demonstrates significant efficacy in caveolin-1-expressing tumors. Molecular Therapy Oncolytics, 22(24): 555-564. PMID: 34553040. PMCID: PMC8433067.
- Sebastian NT, Webb A, Merrell KW, Koay EJ, Wolfe AR, Zhang L, Wilhite TJ, Elganainy D, Robb R, Chen W, Cloyd J, Dillhoff M, Tsung A, Abushahin L, Noonan A, Williams TM. Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2021 Oct 15;13(20):5168. PMID: 34680317; PMCID: PMC8534163.
- Shen C, Shyu DL, Xu M, Yang L, Webb A, Duan W, Williams TM. De-regulation of AKT-mTOR signaling contributes to chemoradiation resistance in lung squamous cell carcinoma. Mol Cancer Res. 2022 Mar 1; 20(3):425-433. doi: 10.1158/1541-7786.MCR-21-0272. PMID: 34810212 PMCID: PMC8898295.
- Williams TM, Schneeweiss A, Jackisch C, Shen C, Weber KE, Fasching PA, Denkert C, Furlanetto J, Heinmöller E, Schmatloch S, Karn T, Szeto CW, van Mackelenbergh MT, Nekljudova V, Stickeler E, Soon-Shiong P, Schem C, Mairinger T, Müller V, Marme F, Untch M, Loibl S. Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial. Clin Cancer Res. 2023 Sep 1;29(17):3384-3394. doi: 10.1158/1078-0432.CCR-23-0362. PMID: 37432976; PMCID: PMC10530448.
- Corrales-Guerrero S, Cui T, Castro-Aceituno V, Yang L, Nair S, Feng H, Venere M, Yoon S, DeWees T, Shen C, Williams TM. Inhibition of RRM2 radiosensitizes glioblastoma and uncovers synthetic lethality in combination with targeting CHK1. Cancer Lett. 2023 Aug 28;570:216308. doi: 10.1016/j.canlet.2023.216308. Epub 2023 Jul 22. PMID: 37482342.
- Yang L, Li Z, Binzel DW, Guo P, Williams TM. Targeting oncogenic KRAS in non-small cell lung cancer with EGFR aptamer-conjugated multifunctional RNA nanoparticles. Mol Ther Nucleic Acids. 2023 Jul 28;33:559-571. doi: 10.1016/j.omtn.2023.07.027. PMID: 37637206; PMCID: PMC10448464.
- Sebastian NT, Webb A, Shilo K, Robb R, Xu-Welliver M, Haglund K, Brownstein J, DeNicola GM, Shen C, Williams TM. A PI3K gene expression signature predicts for recurrence in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy (SBRT). Cancer. 2023 Aug 10. doi: 10.1002/cncr.34983. Epub ahead of print. PMID: 37560930.
- Cui T, Corrales-Guerrero S, Castro-Aceituno V, Nair S, Maneval DC, Monnig C, Kearney P, Ellis S, Raheja N, Raheja N, Williams TM. JNTX-101, a novel albumin-encapsulated gemcitabine prodrug, is efficacious and operates via caveolin-1-mediated endocytosis. Mol Ther Oncolytics. 2023. Aug 18;30:181-192. PMID: 37674628.
- Liu Y, Corrales-Guerrero S, Kuo JC, Robb R, Nagy G, Cui T, Lee RJ, Williams TM. Improved Targeting and Safety of Doxorubicin through a Novel Albumin Binding Prodrug Approach. ACS Omega. 2023 Dec 21;9(1):977-987. PMID: 38222540; PMCID: PMC10785662.
- Wolfe AR†, Cui T†, Baie S, Corrales-Guerrero S, Webb A, Castro-Aceituno V, Shyu DL, Karasinska JM, Topham JT, Renouf DJ, Schaeffer DF, Halloran M, Packard R, Robb R, Chen W, Denko N, Lisanti M, Thompson TC, Frank P, Williams TM. Nutrient Scavenging Fueled Growth in Pancreatic Cancer Depends on Caveolae-Mediated Endocytosis Under Nutrient Deprivation Conditions. Science Advances. 2024. In press. †co-first authors.